tiprankstipranks
Trending News
More News >
Suzhou Basecare Medical Corp. Ltd. Class H (HK:2170)
:2170
Hong Kong Market
Advertisement

Suzhou Basecare Medical Corp. Ltd. Class H (2170) AI Stock Analysis

Compare
0 Followers

Top Page

HK:2170

Suzhou Basecare Medical Corp. Ltd. Class H

(2170)

Rating:49Neutral
Price Target:
HK$3.00
▲(6.38%Upside)
The overall stock score is primarily influenced by financial performance challenges, with strong revenue growth offset by high operating costs and leverage risks. Technical analysis suggests a lack of positive momentum, and the valuation is weakened by a negative P/E ratio. These factors collectively indicate potential concerns for investors.

Suzhou Basecare Medical Corp. Ltd. Class H (2170) vs. iShares MSCI Hong Kong ETF (EWH)

Suzhou Basecare Medical Corp. Ltd. Class H Business Overview & Revenue Model

Company DescriptionSuzhou Basecare Medical Corp. Ltd. Class H (2170) is a China-based biotechnology company specializing in genetic testing and precision medicine. The company provides comprehensive solutions and services in the fields of reproductive health, oncology, and other genetic disorders. Leveraging advanced technologies and a robust R&D infrastructure, Suzhou Basecare Medical Corp. aims to enhance diagnostic accuracy and therapeutic outcomes for its healthcare partners and patients.
How the Company Makes MoneySuzhou Basecare Medical Corp. Ltd. primarily generates revenue through the sale of genetic testing kits and precision medicine solutions. The company's revenue streams include direct sales to hospitals and healthcare providers, partnerships with research institutions for collaborative developments, and licensing agreements for proprietary technologies. Additionally, Suzhou Basecare may derive income from government grants and subsidies aimed at promoting innovation in biotechnology. The company's focus on R&D and strategic alliances with industry leaders further bolster its market position and financial performance.

Suzhou Basecare Medical Corp. Ltd. Class H Financial Statement Overview

Summary
Suzhou Basecare Medical Corp. Ltd. demonstrates strong revenue growth, driven by increased sales, yet struggles with profitability due to high operating costs. The balance sheet shows a stable equity base but is overshadowed by high leverage, posing risks to financial stability. Persistent operational cash deficits highlight ongoing challenges in cash flow generation.
Income Statement
55
Neutral
The company shows strong revenue growth with a consistent increase in total revenue over the years, indicating solid sales expansion. However, the net profit margin remains negative due to high operating expenses, impacting overall profitability. The gross profit margin is healthy, suggesting effective cost management in production, but the negative EBIT and EBITDA margins highlight ongoing challenges in operating efficiency.
Balance Sheet
60
Neutral
The balance sheet reflects a stable equity base with a solid equity ratio, indicating strong capital structure. However, the high debt-to-equity ratio suggests potential leverage risk. The positive cash and short-term investments position bolsters liquidity, yet the negative net income limits return on equity, which remains a concern for investors.
Cash Flow
50
Neutral
The cash flow statement shows consistent negative operating cash flow, raising concerns about the company's ability to generate cash from its core operations. The free cash flow position is improving, yet still negative, highlighting challenges in sustaining growth without external financing. The inability to convert operating cash flow to net income efficiently is a key area that needs attention.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue299.11M207.98M140.90M107.30M81.11M
Gross Profit136.22M91.35M59.53M51.15M27.71M
EBITDA-253.30M-174.14M-117.73M-118.88M-873.32M
Net Income-237.03M-191.69M-123.16M-143.65M-877.05M
Balance Sheet
Total Assets1.67B1.90B1.78B1.80B350.30M
Cash, Cash Equivalents and Short-Term Investments684.63M945.71M1.33B1.52B192.32M
Total Debt328.42M281.92M75.54M48.57M31.47M
Total Liabilities527.47M499.98M188.33M85.85M68.96M
Stockholders Equity1.14B1.40B1.59B1.72B281.33M
Cash Flow
Free Cash Flow-322.41M-371.44M-317.52M-234.71M-72.38M
Operating Cash Flow-229.12M-267.23M-188.77M-197.85M-64.29M
Investing Cash Flow-181.19M-324.81M-88.70M-56.60M33.53M
Financing Cash Flow33.78M190.55M23.51M1.60B207.47M

Suzhou Basecare Medical Corp. Ltd. Class H Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.82
Price Trends
50DMA
2.86
Positive
100DMA
3.09
Negative
200DMA
2.95
Negative
Market Momentum
MACD
-0.01
Negative
RSI
55.69
Neutral
STOCH
87.68
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2170, the sentiment is Positive. The current price of 2.82 is above the 20-day moving average (MA) of 2.81, below the 50-day MA of 2.86, and below the 200-day MA of 2.95, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 55.69 is Neutral, neither overbought nor oversold. The STOCH value of 87.68 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2170.

Suzhou Basecare Medical Corp. Ltd. Class H Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
HK$17.07B6.10-7.44%2.88%11.55%-28.15%
55
Neutral
€5.47B-10.43%36.76%42.89%
54
Neutral
HK$1.45B-8.64%-20.99%45.74%
52
Neutral
HK$3.06B-2.19%5.32%89.43%
49
Neutral
HK$768.61M-18.64%41.62%-22.27%
46
Neutral
HK$1.27B-27.82%-6.12%0.43%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2170
Suzhou Basecare Medical Corp. Ltd. Class H
2.82
1.05
59.32%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
2.88
-2.74
-48.75%
HK:2216
Broncus Holding Corp.
2.75
2.21
409.26%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.27
0.51
67.11%
HK:9996
Peijia Medical Ltd.
8.18
5.60
217.05%

Suzhou Basecare Medical Corp. Ltd. Class H Corporate Events

Suzhou Basecare Medical Updates Nomination Committee for Governance Compliance
Jun 25, 2025

Suzhou Basecare Medical Corp. Ltd. announced changes to its Nomination Committee to align with the revised Corporate Governance Code effective from July 1, 2025. The appointment of Ms. Jiang Junchao and Dr. Yeung Shu Biu William as new members is expected to enhance the company’s governance structure and compliance with regulatory requirements.

Suzhou Basecare Medical Enhances Governance with New Nomination Committee
Jun 25, 2025

Suzhou Basecare Medical Corporation Limited has established a Nomination Committee as a specialized body under its Board to oversee the selection of candidates for directors and senior management positions. This move is designed to improve the company’s corporate governance by ensuring a well-structured and rationalized board composition, which is expected to positively impact its operational efficiency and strategic decision-making.

Suzhou Basecare Medical Announces AGM and Shareholder Meeting Results
Jun 5, 2025

Suzhou Basecare Medical Corp. Ltd. announced the poll results of its 2024 Annual General Meeting and the 2025 First Class Meetings for various shareholders. While most resolutions were passed, a resolution at the H Shareholders Class Meeting was not approved. The meetings were conducted in compliance with relevant laws and regulations, and the results are considered lawful and valid. This announcement reflects the company’s ongoing governance processes and may impact its shareholder relations and strategic decisions moving forward.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2025